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INTRODUCTION
It appears that circulating vitamin D, the parent compound for tissue vitamin D activation, has an important direct physiological role beyond what was originally anticipated through the local tissue autocrine system [1] . A number of studies have suggested a link between low levels of 25-hydroxy vitamin D [25(OH)D] and the incidence of both acute and chronic pain [2] [3] [4] [5] . Clinical studies of vitamin D supplementation in patients with known vitamin D deficiency have shown mixed results in improving pain scores [6] . Vitamin D is cheap and has relatively few adverse effects. Its use in chronic pain could therefore be advocated even if the benefit was of modest size [4] . In general, there is a positive public perception of vitamin supplementation which could result in high rates of adherence [4] . There appear to be potential genetic polymorphisms in key genes with vitamin D exposure that can influence bioavailability, transport, and distribution in lipid storage pools, metabolism, and action of vitamin D [8] .
Chronic Pain
The International Association for the Study of Pain (IASP) defines chronic pain as ''pain that has persisted beyond normal tissue healing time''. This is taken (in absence of other criteria) to be 3 months [11] . However, some chronic pain disorders are characterized by recurrent short acute episodes and exacerbations such as trigeminal neuralgia and rheumatoid arthritis.
Chronic pain can be produced after tissue damage (or inflammation), nerve damage, and after alteration of normal neural function. Chronic persistent pain leads to chemical, functional, and anatomical changes throughout the nervous system (in the periphery, spinal cord, and brain) [12] [13] [14] . In chronic pain states, the nervous system is altered to produce spontaneous pain that arises without any apparent peripheral stimulus as well as a hypersensitivity to peripheral stimuli [15] [16] [17] [18] . Pain hypersensitivity potentiates hyperalgesia (the exaggerated and prolonged response to noxious stimulation) and allodynia (pain resulting from a stimulus that is normally nonpainful) [19] . Reduced descending inhibition in the central nervous system results in increased peripheral noxious signals that provide messages to the brain, and result in an increased experience of pain [20] . Vitamin D supplementation has been found to improve bone density and musculoskeletal symptoms [26] . Vitamin D deficiency causes muscle weakness and pain in children and adults [27, 28] . Low bone density and osteopenia appear to contribute to chronic pain in patients with cystic fibrosis, and are related to low 25(OH)D levels [29, 30] .
THE INTERFACE OF VITAMIN D AND CHRONIC PAIN
Low 25(OH)D levels have been found to be related to heightened central sensitivity (particularly augmented pain processing) upon mechanical stimulation in chronic pain patients [31] . Migraine and fibromyalgia represent a central neural hypersensitivity [32, 33] . Activated microglia, astrocytes, and spinal glia release a variety of neuroexcitatory substances (nitric oxide, excitatory amino acids, proinflammatory cytokines, and mediators) that potentially initiate and maintain the neural hypersensitivity state seen in chronic pain states [32] . As a neuroactive steroid, vitamin D can modulate neuronal excitability including spontaneous regular firing, action potential duration, intrinsic excitability and sensitivity to neurotransmitters (gonadotropinreleasing hormone, opioidergic neurons) as well as to neurotransmitter receptors such as gammaaminobutyric acid and N-methyl-D-aspartate [34] [35] [36] . Vitamin D plays a fundamental role in astrocyte detoxification pathways, and thereby exerts a neuroprotective effect [37] . Vitamin D suppresses tumor necrosis factor alpha (TNFa), macrophage colony-stimulating factor (M-CSF), and inducible nitric oxide synthase in astrocytes and microglia [38] . TNFa has been convincingly implicated at both peripheral and central levels of sensitization [39] . M-CSF is a cytokine that stimulates proliferation, differentiation, and survival of monocytes and macrophages.
Macrophages can release many inflammatory mediators, including proinflammatory cytokines, particularly TNFa and interleukin-1 beta (IL-1b), nerve growth factor (NGF), nitric oxide (NO), and the prostanoids [40] . By limiting M-CSF, vitamin D has the potential to inhibit pain pathways. The presence of VDR, 1a-hydroxylase, and DBP in the hypothalamus is suggested as the mechanism by which vitamin D deficiency is implicated in the pathophysiology of various primary headache disorders [41] .
Vitamin D upregulates the synthesis of neurotrophins such as NGF, neurotrophin 3, and glial cell line-derived neurotrophic factor, whereas neurotrophin 4 is down-regulated [37, 38, [42] [43] [44] [63, 64] ; the reason for this is that the major stimulus for PTH secretion is a low level of serum calcium [7, 65] . It is generally agreed that the levels of PTH 
EVIDENCE FROM RECENT RANDOMIZED PLACEBO-CONTROLLED TRIALS OF VITAMIN D SUPPLEMENTATION IN PATIENTS WITH CHRONIC PAIN
There are limited randomized double-blind placebo-controlled trials of vitamin D supplementation to determine the efficacy of Clinical symptoms related to knee OA were assessed with the WOMAC index (which assesses pain, stiffness, function, and interpretation response in terms of a 5-point scale). Knee pain also was assessed using the VAS The patients were followed for conditions. Eight RCTs met these inclusion criteria.
Seventy-eight studies were excluded based on the following criteria, namely: pain not measured as an outcome (n = 25); acute pain instead of chronic pain (n = 4); study was singly blinded or not specifically described as double blinded (n = 6); study design only (n = 1); not all participants had chronic pain (n = 1); there was no supplementation with vitamin D (n = 4); and the study did not control for vitamin D independent of other treatments (n = 37). Only one reason for exclusion was stated. However, some studies may have had more than one reason for exclusion (see Table   S1 in the electronic supplementary material for details). The 8 data sets ranged in size from 24 to 146 participants. The total number of participants in the ''pain'' and ''control'' groups was 620 of which 396 were female. The majority of the studies were of high methodological quality (Oxford Quality Score 5/5) suggesting little likelihood of methodological bias [90] . There were five studies related to musculoskeletal pain [91] [92] [93] [94] [95] , of which two were of diffuse or generalized musculoskeletal pain [91, 92] . There were three studies of specific musculoskeletal pain, two involving osteoarthritis of the knees and one of aromatase inhibitor-induced musculoskeletal pain [93] [94] [95] . There was one study of each of 
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